ストックスクリーナーアプリを入手
16.33
10.86%
1.60
アフターアワーズ：
16.59
0.26
+1.59%
Climb Bio Inc (CLYM) 最新ニュース
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYM - MarketBeat
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Climb Bio Collaborator Beijing Mabworks Begins Phase 2 Trial Dosing for IgA Nephropathy in China - Kalkine Media
Climb Bio (NASDAQ:CLYM) Shares Up 8.2%Still a Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Climb Bio Advances Phase 2 Renal Disease Trial - TipRanks
Climb Bio and Mabworks begin dosing in Phase 2 trial for kidney disease in China - Investing.com Canada
Form 8K Climb Bio Inc For: 14 August By Investing.com - Investing.com Canada
Climb Bio (NASDAQ:CLYM) Hits New 12-Month HighWhat's Next? - MarketBeat
Renaissance Technologies LLC Lowers Holdings in Climb Bio, Inc. $CLYM - MarketBeat
We Think Climb Bio (NASDAQ:CLYM) Can Afford To Drive Business Growth - moomoo.com
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Climb Bio (NASDAQ:CLYM) Hits New 12-Month High Following Strong Earnings - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $25.00 - MarketBeat
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20 - Moomoo
CLIMB BIO INC : TRUIST SECURITIES RAISES TARGET PRICE TO $25 FROM $17 - Bitget
Climb Bio, Inc. Stock 12‑Month Price Target Raised to $21.93, Implies 76% Upside - TradingView
Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data - TipRanks
Climb Bio Releases Q2 2026 Financial Results - AlphaStreet
Climb Bio Reports Q2 2026 Financial Results and Pipeline Updates in Nasdaq 10-Q Filing - Kalkine Media
Climb Bio, Inc. Q2 2026: Net loss $(13.5M), EPS $(0.18) — 10-Q Summary - TradingView
CLYM: $239.2M cash, $13.5M Q2 net loss, and $103.4M raised to fund clinical pipeline into 2028 - TradingView
Climb Bio (Nasdaq: CLYM) raises $103M, extends cash runway into 2028 - Stock Titan
Climb Bio reports Q2 2026: $239.2M cash, net loss $13.5M; advances CLYM116 and budoprutug programs - TradingView
CLYM: Advanced clinical pipeline and secured $239M cash, extending runway into 2028 - tradingview.com
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Climb Bio Q2 net loss widens on pipeline advancement - TradingView
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Climb Bio (CLYM) Projected to Post Earnings on Tuesday - MarketBeat
Climb Bio (NASDAQ:CLYM) Rating Increased to Moderate Buy at Royal Bank Of Canada - MarketBeat
CLIMB BIO INC : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $23 - Bitget
RBC Capital Initiates Climb Bio at Outperform With $23 Price Target - marketscreener.com
RBC Capital Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $23 - moomoo.com
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst - TipRanks
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesBanking Earnings Report - dars.gov.et
ADAR1 Capital Management LLC Sells 834,813 Shares of Climb Bio, Inc. $CLYM - MarketBeat
Climb Bio Inc (CLYM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Climb Bio Builds Momentum With Late-2026 Data Readouts; Wedbush Sets $20 Target - RTTNews
CLYM Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating - Moomoo
Climb Bio Inc (CLYM) Cash Flow - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Wedbush Forecasts Strong Price Appreciation for Climb Bio (NASDAQ:CLYM) Stock - MarketBeat
CLYM|Climb Bio Inc|Price:12.780|Chg%:-0.060 - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Climb Bio Inc. (CLYM) Edges Higher as Stock Tests Key ResistanceStock Analysis - dars.gov.et
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility (CLYM) - Seeking Alpha
Frontier tech research, news & data - MLQ.ai
Climb Bio (NASDAQ:CLYM) Shares Up 6.7%Should You Buy? - MarketBeat
Climb Bio (NASDAQ:CLYM) Trading Down 8.4%What's Next? - MarketBeat
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
FMR LLC's Strategic Acquisition of Climb Bio Inc Shares - GuruFocus
Q32 Bio Shares Climb Ahead of Drug Trial Results for Alopecia Treatment - Moomoo
Climb Bio Inc. (CLYM) Edges Lower Amid Mixed Biotech Sentiment, Key Support Levels in FocusWeak Sell Signals - DonanımHaber
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineRevenue Per Share - dars.gov.et
Climb Bio, Inc. advances CD19-based approach to preserve protective antibody function - Traders Union
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
CLYM Q1 2026 Earnings: Narrower Loss than Expected, Stock Edges HigherPost-Announcement Reaction - DonanımHaber
Form 13D/A Climb Bio For: 7 July By Investing.com - Investing.com Nigeria
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):